To conclude, this untargeted peptidomic analysis to identify the effect of GLP-1R agonist treatment on the urinary peptidome of T2DM patients indicated as a prominent finding the downregulation of MMP proteases, as predicted based on the observed collagen peptide changes following GLP-1R agonist treatment. Here, GLP1R is linked to type 2 diabetes mellitus.